Abstract

IntroductionNatalizumab treatment for relapsing remitting multiple sclerosis (RRMS) is associated with a risk of progressive multifocal leukoencephalopathy (PML) due to reactivation of latent JC virus (JCV). We prospectively screened for...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call